Skip to main content
Top
Published in: Journal of Nephrology 1/2019

Open Access 01-02-2019 | Original Article

Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease

Authors: Tobias Feldreich, Christoph Nowak, Tove Fall, Axel C. Carlsson, Juan-Jesus Carrero, Jonas Ripsweden, Abdul Rashid Qureshi, Olof Heimbürger, Peter Barany, Peter Stenvinkel, Nicolas Vuilleumier, Philip A. Kalra, Darren Green, Johan Ärnlöv

Published in: Journal of Nephrology | Issue 1/2019

Login to get access

Abstract

Introduction

Proteomic profiling of end-stage renal disease (ESRD) patients could lead to improved risk prediction and novel insights into cardiovascular disease mechanisms. Plasma levels of 92 cardiovascular disease-associated proteins were assessed by proximity extension assay (Proseek Multiplex CVD-1, Olink Bioscience, Uppsala, Sweden) in a discovery cohort of dialysis patients, the Mapping of Inflammatory Markers in Chronic Kidney disease cohort [MIMICK; n = 183, 55% women, mean age 63 years, 46 cardiovascular deaths during follow-up (mean 43 months)]. Significant results were replicated in the incident and prevalent hemodialysis arm of the Salford Kidney Study [SKS dialysis study, n = 186, 73% women, mean age 62 years, 45 cardiovascular deaths during follow-up (mean 12 months)], and in the CKD5-LD-RTxcohort with assessments of coronary artery calcium (CAC)-score by cardiac computed tomography (n = 89, 37% women, mean age 46 years).

Results

In age and sex-adjusted Cox regression in MIMICK, 11 plasma proteins were nominally associated with cardiovascular mortality (in order of significance: Kidney injury molecule-1 (KIM-1), Matrix metalloproteinase-7, Tumour necrosis factor receptor 2, Interleukin-6, Matrix metalloproteinase-1, Brain-natriuretic peptide, ST2 protein, Hepatocyte growth factor, TNF-related apoptosis inducing ligand receptor-2, Spondin-1, and Fibroblast growth factor 25). Only plasma KIM-1 was associated with cardiovascular mortality after correction for multiple testing, but also after adjustment for dialysis vintage, cardiovascular risk factors and inflammation (hazard ratio) per standard deviation (SD) increase 1.84, 95% CI 1.26–2.69, p = 0.002. Addition of KIM-1, or nine of the most informative proteins to an established risk-score (modified AROii CVM-score) improved discrimination of cardiovascular mortality risk from C = 0.777 to C = 0.799 and C = 0.823, respectively. In the SKS dialysis study, KIM-1 predicted cardiovascular mortality in age and sex adjusted models (hazard ratio per SD increase 1.45, 95% CI 1.03–2.05, p = 0.034) and higher KIM-1 was associated with higher CACscores in the CKD5-LD-RTx-cohort.

Conclusions

Our proteomics approach identified plasma KIM-1 as a risk marker for cardiovascular mortality and coronary artery calcification in three independent ESRD-cohorts. The improved risk prediction for cardiovascular mortality by plasma proteomics merit further studies.
Appendix
Available only for authorised users
Literature
2.
go back to reference Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J et al (2016) US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 67(3 Suppl 1):S1-305 Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J et al (2016) US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 67(3 Suppl 1):S1-305
3.
go back to reference Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R, Pisoni RL (2016) Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet 388(10041):294–306CrossRef Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R, Pisoni RL (2016) Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet 388(10041):294–306CrossRef
4.
go back to reference Stenvinkel P (2010) Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 268(5):456–467. (Epub 2010/09/03 06:00)CrossRef Stenvinkel P (2010) Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 268(5):456–467. (Epub 2010/09/03 06:00)CrossRef
5.
go back to reference de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D et al (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302(16):1782–1789CrossRef de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D et al (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302(16):1782–1789CrossRef
6.
go back to reference Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3(2):505–521CrossRef Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3(2):505–521CrossRef
7.
go back to reference Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S et al (2014) Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 18(19):2918–2926PubMed Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S et al (2014) Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 18(19):2918–2926PubMed
8.
go back to reference Fu Q, Cao L, Li H, Wang B, Li Z (2014) Cardiorenal syndrome: pathophysiological mechanism, preclinical models, novel contributors and potential therapies. Chin Med J (Engl) 127(16):3011–3018 Fu Q, Cao L, Li H, Wang B, Li Z (2014) Cardiorenal syndrome: pathophysiological mechanism, preclinical models, novel contributors and potential therapies. Chin Med J (Engl) 127(16):3011–3018
9.
go back to reference Kooman JP, Dekker MJ, Usvyat LA, Kotanko P, van der Sande FM, Schalkwijk CG et al (2017) Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Renal Physiol 313(4):F938–F950CrossRef Kooman JP, Dekker MJ, Usvyat LA, Kotanko P, van der Sande FM, Schalkwijk CG et al (2017) Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Renal Physiol 313(4):F938–F950CrossRef
10.
go back to reference Liu J, Zhu W, Jiang CM, Feng Y, Xia YY, Zhang QY et al (2018) Activation of the mTORC1 pathway by inflammation contributes to vascular calcification in patients with end-stage renal disease. J Nephrol 14(10):018–0486 Liu J, Zhu W, Jiang CM, Feng Y, Xia YY, Zhang QY et al (2018) Activation of the mTORC1 pathway by inflammation contributes to vascular calcification in patients with end-stage renal disease. J Nephrol 14(10):018–0486
11.
go back to reference Weissinger EM, Nguyen-Khoa T, Fumeron C, Saltiel C, Walden M, Kaiser T et al (2006) Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics 6(3):993–1000CrossRef Weissinger EM, Nguyen-Khoa T, Fumeron C, Saltiel C, Walden M, Kaiser T et al (2006) Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics 6(3):993–1000CrossRef
12.
go back to reference Araujo JE, Jorge S, Teixeira ECF, Ramos A, Lodeiro C, Santos HM et al (2016) A cost-effective method to get insight into the peritoneal dialysate effluent proteome. J Proteomics 145:207–213CrossRef Araujo JE, Jorge S, Teixeira ECF, Ramos A, Lodeiro C, Santos HM et al (2016) A cost-effective method to get insight into the peritoneal dialysate effluent proteome. J Proteomics 145:207–213CrossRef
13.
go back to reference Bonomini M, Sirolli V, Pieroni L, Felaco P, Amoroso L, Urbani A (2015) Proteomic investigations into hemodialysis therapy. Int J Mol Sci 16(12):29508–29521CrossRef Bonomini M, Sirolli V, Pieroni L, Felaco P, Amoroso L, Urbani A (2015) Proteomic investigations into hemodialysis therapy. Int J Mol Sci 16(12):29508–29521CrossRef
14.
go back to reference Tsalik EL, Willig LK, Rice BJ, van Velkinburgh JC, Mohney RP, McDunn JE et al (2015) Renal systems biology of patients with systemic inflammatory response syndrome. Kidney Int 88(4):804–814CrossRef Tsalik EL, Willig LK, Rice BJ, van Velkinburgh JC, Mohney RP, McDunn JE et al (2015) Renal systems biology of patients with systemic inflammatory response syndrome. Kidney Int 88(4):804–814CrossRef
15.
go back to reference Molina H, Bunkenborg J, Reddy GH, Muthusamy B, Scheel PJ, Pandey A (2005) A proteomic analysis of human hemodialysis fluid. Mol Cell Proteom 4(5):637–650CrossRef Molina H, Bunkenborg J, Reddy GH, Muthusamy B, Scheel PJ, Pandey A (2005) A proteomic analysis of human hemodialysis fluid. Mol Cell Proteom 4(5):637–650CrossRef
16.
go back to reference Bonomini M, Sirolli V, Magni F, Urbani A (2012) Proteomics and nephrology. J Nephrol 25(6):865–871CrossRef Bonomini M, Sirolli V, Magni F, Urbani A (2012) Proteomics and nephrology. J Nephrol 25(6):865–871CrossRef
17.
go back to reference Snaedal S, Heimburger O, Qureshi AR, Danielsson A, Wikstrom B, Fellstrom B et al (2009) Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis 53(6):1024–1033CrossRef Snaedal S, Heimburger O, Qureshi AR, Danielsson A, Wikstrom B, Fellstrom B et al (2009) Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis 53(6):1024–1033CrossRef
18.
go back to reference Snaedal S, Qureshi AR, Lund SH, Germanis G, Hylander B, Heimburger O et al (2016) Dialysis modality and nutritional status are associated with variability of inflammatory markers. Nephrol Dial Transpl 31(8):1320–1327CrossRef Snaedal S, Qureshi AR, Lund SH, Germanis G, Hylander B, Heimburger O et al (2016) Dialysis modality and nutritional status are associated with variability of inflammatory markers. Nephrol Dial Transpl 31(8):1320–1327CrossRef
19.
go back to reference Chiu D, Abidin N, Johnstone L, Chong M, Kataria V, Sewell J et al (2016) Novel approach to cardiovascular outcome prediction in haemodialysis patients. Am J Nephrol 43(3):143–152CrossRef Chiu D, Abidin N, Johnstone L, Chong M, Kataria V, Sewell J et al (2016) Novel approach to cardiovascular outcome prediction in haemodialysis patients. Am J Nephrol 43(3):143–152CrossRef
20.
go back to reference Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A et al (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88(6):1356–1364CrossRef Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A et al (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88(6):1356–1364CrossRef
21.
go back to reference Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S (2011) Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 39(15):e102CrossRef Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S (2011) Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 39(15):e102CrossRef
22.
go back to reference Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D et al (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9(4):e95192CrossRef Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D et al (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9(4):e95192CrossRef
23.
go back to reference Tibshirani R (1996) Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol 58:267–288 Tibshirani R (1996) Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol 58:267–288
24.
go back to reference Anker SD, Gillespie IA, Eckardt KU, Kronenberg F, Richards S, Drueke TB et al (2016) Development and validation of cardiovascular risk scores for haemodialysis patients. Int J Cardiol 216:68–77CrossRef Anker SD, Gillespie IA, Eckardt KU, Kronenberg F, Richards S, Drueke TB et al (2016) Development and validation of cardiovascular risk scores for haemodialysis patients. Int J Cardiol 216:68–77CrossRef
25.
go back to reference Critselis E, Lambers Heerspink H (2016) Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression. Nephrol Dial Transpl 31(2):249–254 Critselis E, Lambers Heerspink H (2016) Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression. Nephrol Dial Transpl 31(2):249–254
26.
go back to reference Wang H, Lin ZT, Yuan Y, Wu T (2016) Urine biomarkers in renal allograft. J Transl Int Med 4(3):109–113CrossRef Wang H, Lin ZT, Yuan Y, Wu T (2016) Urine biomarkers in renal allograft. J Transl Int Med 4(3):109–113CrossRef
27.
go back to reference Lindhardt M, Persson F, Zurbig P, Stalmach A, Mischak H, de Zeeuw D et al (2016) Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transpl 31:1866–1873 Lindhardt M, Persson F, Zurbig P, Stalmach A, Mischak H, de Zeeuw D et al (2016) Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transpl 31:1866–1873
28.
go back to reference Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12):e15004CrossRef Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12):e15004CrossRef
29.
go back to reference Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H et al (2015) New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrol Dial Transpl 30(11):1842–1852CrossRef Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H et al (2015) New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrol Dial Transpl 30(11):1842–1852CrossRef
30.
go back to reference Rennert PD (2011) Novel roles for TIM-1 in immunity and infection. Immunol Lett 141(1):28–35CrossRef Rennert PD (2011) Novel roles for TIM-1 in immunity and infection. Immunol Lett 141(1):28–35CrossRef
31.
go back to reference Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK (2005) The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med 11(8):362–369CrossRef Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK (2005) The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med 11(8):362–369CrossRef
32.
33.
go back to reference Schiffl H, Lang SM (2012) Update on biomarkers of acute kidney injury: moving closer to clinical impact? Mol Diagn Ther 16(4):199–207CrossRef Schiffl H, Lang SM (2012) Update on biomarkers of acute kidney injury: moving closer to clinical impact? Mol Diagn Ther 16(4):199–207CrossRef
34.
go back to reference Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X et al (2017) Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: the CRIC study. Clin J Am Soc Nephrol 12(5):761–771CrossRef Park M, Hsu CY, Go AS, Feldman HI, Xie D, Zhang X et al (2017) Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: the CRIC study. Clin J Am Soc Nephrol 12(5):761–771CrossRef
35.
go back to reference Foster MC, Coresh J, Bonventre JV, Sabbisetti VS, Waikar SS, Mifflin TE et al (2015) Urinary biomarkers and risk of ESRD in the atherosclerosis risk in communities study. Clin J Am Soc Nephrol 10(11):1956–1963CrossRef Foster MC, Coresh J, Bonventre JV, Sabbisetti VS, Waikar SS, Mifflin TE et al (2015) Urinary biomarkers and risk of ESRD in the atherosclerosis risk in communities study. Clin J Am Soc Nephrol 10(11):1956–1963CrossRef
36.
go back to reference Bonventre JV (2014) Kidney injury molecule-1: a translational journey. Trans Am Clin Climatol Assoc 125:293–299 (discussion 9) PubMedPubMedCentral Bonventre JV (2014) Kidney injury molecule-1: a translational journey. Trans Am Clin Climatol Assoc 125:293–299 (discussion 9) PubMedPubMedCentral
37.
go back to reference Driver TH, Katz R, Ix JH, Magnani JW, Peralta CA, Parikh CR et al (2014) Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Kidney Dis 64(1):49–56CrossRef Driver TH, Katz R, Ix JH, Magnani JW, Peralta CA, Parikh CR et al (2014) Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Kidney Dis 64(1):49–56CrossRef
38.
go back to reference Tonkonogi A, Carlsson AC, Helmersson-Karlqvist J, Larsson A, Arnlov J (2016) Associations between urinary kidney injury biomarkers and cardiovascular mortality risk in elderly men with diabetes. Ups J Med Sci 121(3):174–178CrossRef Tonkonogi A, Carlsson AC, Helmersson-Karlqvist J, Larsson A, Arnlov J (2016) Associations between urinary kidney injury biomarkers and cardiovascular mortality risk in elderly men with diabetes. Ups J Med Sci 121(3):174–178CrossRef
39.
go back to reference Tian L, Shao X, Xie Y, Wang Q, Che X, Zhang M et al (2017) Kidney injury molecule-1 is elevated in nephropathy and mediates macrophage activation via the Mapk signalling pathway. Cell Physiol Biochem 41(2):769–783CrossRef Tian L, Shao X, Xie Y, Wang Q, Che X, Zhang M et al (2017) Kidney injury molecule-1 is elevated in nephropathy and mediates macrophage activation via the Mapk signalling pathway. Cell Physiol Biochem 41(2):769–783CrossRef
40.
go back to reference Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A et al (2014) Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 25(10):2177–2186CrossRef Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A et al (2014) Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 25(10):2177–2186CrossRef
41.
go back to reference Alderson HV, Ritchie JP, Pagano S, Middleton RJ, Pruijm M, Vuilleumier N et al (2016) The associations of blood kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin with progression from CKD to ESRD. Clin J Am Soc Nephrol 11(12):2141–2149CrossRef Alderson HV, Ritchie JP, Pagano S, Middleton RJ, Pruijm M, Vuilleumier N et al (2016) The associations of blood kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin with progression from CKD to ESRD. Clin J Am Soc Nephrol 11(12):2141–2149CrossRef
42.
go back to reference Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL et al (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273(7):4135–4142CrossRef Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL et al (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273(7):4135–4142CrossRef
43.
go back to reference van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA (2007) Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 212(2):209–217CrossRef van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA (2007) Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 212(2):209–217CrossRef
44.
go back to reference Paapstel K, Zilmer M, Eha J, Tootsi K, Piir A, Kals J (2016) Early biomarkers of renal damage in relation to arterial stiffness and inflammation in male coronary artery disease patients. Kidney Blood Press Res 41(4):488–497CrossRef Paapstel K, Zilmer M, Eha J, Tootsi K, Piir A, Kals J (2016) Early biomarkers of renal damage in relation to arterial stiffness and inflammation in male coronary artery disease patients. Kidney Blood Press Res 41(4):488–497CrossRef
45.
go back to reference Yang H, Young DW, Gusovsky F, Chow JC (2000) Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem 275(27):20861–20866CrossRef Yang H, Young DW, Gusovsky F, Chow JC (2000) Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem 275(27):20861–20866CrossRef
46.
go back to reference Ravingerova T, Barancik M, Strniskova M (2003) Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247(1–2):127–138CrossRef Ravingerova T, Barancik M, Strniskova M (2003) Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247(1–2):127–138CrossRef
47.
go back to reference Javadov S, Jang S, Agostini B (2014) Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. Pharmacol Ther 144(2):202–225CrossRef Javadov S, Jang S, Agostini B (2014) Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. Pharmacol Ther 144(2):202–225CrossRef
48.
go back to reference Kim HS, Asmis R (2017) Mitogen-activated protein kinase phosphatase 1 (MKP-1) in macrophage biology and cardiovascular disease. A redox-regulated master controller of monocyte function and macrophage phenotype. Free Radic Biol Med 19(17):30156–30159 Kim HS, Asmis R (2017) Mitogen-activated protein kinase phosphatase 1 (MKP-1) in macrophage biology and cardiovascular disease. A redox-regulated master controller of monocyte function and macrophage phenotype. Free Radic Biol Med 19(17):30156–30159
49.
go back to reference Sun J, Axelsson J, Machowska A, Heimburger O, Barany P, Lindholm B et al (2016) Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol 11(7):1163–1172CrossRef Sun J, Axelsson J, Machowska A, Heimburger O, Barany P, Lindholm B et al (2016) Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol 11(7):1163–1172CrossRef
50.
go back to reference Zhang W, He J, Zhang F, Huang C, Wu Y, Han Y et al (2013) Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol 26(2):243–253CrossRef Zhang W, He J, Zhang F, Huang C, Wu Y, Han Y et al (2013) Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol 26(2):243–253CrossRef
Metadata
Title
Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease
Authors
Tobias Feldreich
Christoph Nowak
Tove Fall
Axel C. Carlsson
Juan-Jesus Carrero
Jonas Ripsweden
Abdul Rashid Qureshi
Olof Heimbürger
Peter Barany
Peter Stenvinkel
Nicolas Vuilleumier
Philip A. Kalra
Darren Green
Johan Ärnlöv
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 1/2019
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-018-0556-5

Other articles of this Issue 1/2019

Journal of Nephrology 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.